Montgomery Joins Alder Board

Xconomy Seattle — 

Alder Biopharmaceuticals, the Bothell, WA-based developer of antibody drugs, said today it has added veteran drug developer Bruce Montgomery to its board of directors. Montgomery, 57, most recently served as senior vice president of respiratory drugs at Gilead Sciences (NASDAQ: GILD) in Seattle. Montgomery stepped down from Gilead in August to look for new opportunities, and last month he joined the board of Seattle-based Geospiza. Alder, which was profiled in Xconomy in January, is seeking to use a yeast-based technology that it hopes will provide a faster, cheaper method for creating targeted antibody drugs against cancer and autoimmune diseases